News from mirati therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 11, 2014, 08:00 ET

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum...

Aug 08, 2014, 08:00 ET

Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided...

Jun 30, 2014, 16:01 ET

Mirati Therapeutics Added to Russell 2000 Index

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual...

Jun 17, 2014, 08:00 ET

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan...

Jun 12, 2014, 08:00 ET

Mirati Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference...

May 22, 2014, 08:00 ET

Mirati Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the Jefferies 2014 Global Healthcare Conference on...

May 15, 2014, 16:01 ET

Mirati Therapeutics Reports First Quarter 2014 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2014 and provided...

Mar 20, 2014, 08:00 ET

William R. Ringo Joins Mirati Board of Directors

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of...

Mar 17, 2014, 16:01 ET

Mirati Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the fourth quarter and year ended December 31, 2013 and...

Feb 05, 2014, 08:00 ET

Mirati Therapeutics to Present at the 2014 Leerink Global Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 2014 Leerink Global Healthcare Conference on...

Dec 09, 2013, 10:10 ET

Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting...

Dec 02, 2013, 08:00 ET

Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference...

Nov 22, 2013, 08:00 ET

Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference...

Nov 12, 2013, 08:00 ET

Mirati Therapeutics Reports Third Quarter 2013 Financial Results

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30,...

Nov 08, 2013, 08:00 ET

Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in...

Oct 23, 2013, 20:13 ET

Mirati Therapeutics Prices Public Offering Of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,250,000 shares of its common stock at...

Oct 16, 2013, 16:15 ET

Mirati Therapeutics Announces Public Offering Of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it is offering to sell 3,000,000 shares of its common stock in an underwritten public...